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Abstracts / Biol Blood Marrow Transplant 21 (2015) S171eS184S174malignancy in 34 patients (64%), lymphoid malignancy in 16
(30%) and plasma cell dyscrasia in 3 (6%). Sixteen (30%) had
myeloablative conditioning. Median time from onset of
symptoms to diagnosis was 2 days (0-15) and median time
from transplant to diagnosis was 11 months (0-48). Twenty-
eight patients (53%) had URTI symptoms at presentation, 11
(21%) had LRTI and 14 (26%) had progression from URTI to
LRTI. Stratifying per the ISI criteria, 16 patients (30%) were
low risk, 31 (59%) were moderate and 6 (11%) were high risk.
Median survival post RSV diagnosis was 17 months (0-78).
Forty-six patients received oral ribavirin, 4 received aero-
solized ribavirin and 3 were not treated. Five patients (3 high
and 2 moderate risk) had RSV associated mortality with a
median time to death of 8 days (7-18) due to respiratory
failure and/or acute respiratory distress syndrome. Case fa-
tality among high, moderate and low risk patients were 50%,
6% and 0%, respectively. Overall survival was statistically
signiﬁcant among the risk groups (P 0.0112). Predicting LRTI
at diagnosis and risk of URTI to LRTI progression was how-
ever not signiﬁcant (P 0.1375 and 0.4505, respectively).
Conclusion: Use of oral ribavirin in low and moderate risk
patients was associated with an excellent outcome. The ISI
predicted survival but not risk of LRTI post RSV infection in
an independent cohort of allogeneic stem cell transplant
recipients treated with oral ribavirin. Elevated case fatality in
high risk cases highlights the need for better therapies in this
group of patients.
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There is a critical need to increase awareness of late compli-
cations and recommended preventive care among patients
and providers and to improve patient-provider and provider-
provider communication about long-term care post-HCT.
During transition from transplant center back to community,
care often becomes fragmented and insufﬁcient to address
survivors’ complexmedical needs.Weconducted focusgroups
to characterize patient-centered elements that will increase
the acceptability of an individualized treatment summary and
survivorship care plan instrument (SCP). A SCPwas developed
that uses disease and transplant related data routinely sub-
mitted by centers to the CIBMTR. The treatment summary
incorporates these data and identiﬁes important treatment
exposures (age, gender, HCT type, GVHD, TBI and steroid). The
care plan uses these risk factors and long-term followup
guidelines (Majhail et al, BBMT/BMT 2012) to provide patient-
speciﬁc recommendations for preventive care. Phone focus
groups (N¼12) were conducted for: 1) adult allogeneic re-
cipients >1 year post-HCT and their caregivers (3 groups,
N¼22); 2) hematology-oncology and primary care practice
physicians/mid-level providers (3 groups, N¼24); 3) HCT cli-
nicians (2 groups, N¼14); and 4) HCT nurses/social workers (4p care and SCP identiﬁed in focus groups.
Figure 1B.
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saturation of key themes (Figure 1). Reliability and validity of
coding were assessed (kappa >.90). Patients/caregivers re-
ported challenges in accessing specialty care due to providers’
unfamiliarity with HCT and felt SCP should be more person-
alized with robust sections on psychosocial, sexual/mental
health, and nutrition/diet. Providers wanted the treatment
history to focus only onwhat theymust know to care for their
patient and found SCP markedly better than what they
currently receive. All preferred to receive SCP electronically;
however, hardcopywas still considered necessary for patients
without computer access. Both patients and providers iden-
tiﬁed that SCPwill facilitate appropriate post-HCTcare. Similar
themes were identiﬁed among the three health professional
groups, with the exception of screening and care for psycho-
social issues that was more frequently brought up by the
nurses/social workers. Our study highlights the need for a SCP
instrument to facilitate HCT survivorship care. Patient and
provider feedback has been used to develop a ﬁnal SCP that is
being tested in a randomized trial.219
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Background: In advanced cancers, patients’ prognostic per-
ceptions inﬂuence their medical decisions. However, little is
known about how patients with hematologic malignancies
undergoing hematopoietic stem cell transplantation (HCT)
and their family caregivers (FC) understand their prognosis.
We examined prognostic perception in these patients during
hospitalization for HCT and its relationship with QOL and
mood.Figure 1A.Methods: We conducted a longitudinal study of patients
(and FC) hospitalized for HCT. At baseline (6 days pre-HCT),
we used a 10-item questionnaire to measure patients’ and FC
information preferences, and perception of prognosis. Using
2 items, we also asked the treating oncologists regarding the
patients’ prognosis. At day-6, day+1, day+8 of HCT, we
assessed QOL (Functional Assessment of Cancer Therapy-
Bone Marrow Transplantation FACT-BMT), and mood
(Hospital Anxiety and Depression Scale). We examined the
relationship between patients’ prognostic perception and
their QOL and mood during hospitalization for HCT using
multivariable linear mixed models.
Results: We enrolled 97% of consecutively eligible patients
undergoing autologous (n¼30), myeloablative (n¼30) or
reduced intensity (n¼30) allogeneic HCT. Most patients (80/
90, 88.9%) and FC (41/47, 87.1%) believed that it is “extremely”
or “very” important to know about prognosis [Figure 1A].
However, the majority of patients (66/85, 77.6%) and FC (33/
46, 71.7%) reported an inaccurate and more optimistic
perception of the patients’ prognosis compared to the
oncologist (P’s < 0.0001) [Figure 1B]. Patients with accurate
prognostic understanding reported lower QOL (P ¼ 0.03)
and worse depressive symptoms (P ¼ 0.04) with a steeper
increase in depression (P ¼ 0.006) over time compared to
patients with an inaccurate optimistic prognostic perception.
Conclusions: The majority of patients and FC reported
inaccurate and more optimistic perception of prognosis
compared with the oncologist. Patients with an accurate
perception of their prognosis had lower QOL, higher
depression, and a steeper increase in depression during
hospitalization for HCT. Interventions are needed to improve
prognostic understanding while providing adequate psy-
chosocial support during HCT.220
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